Alyaa Al-Mughairy/LinkedIn
Jul 18, 2026, 15:31
Alyaa Al-Mughairy: Presenting Real-World Emicizumab Data at the ISTH 2026 Middle East Summit
Alyaa Al-Mughairy, Pediatric Hematology Oncology Senior Consultant at Ministry of Health Oman,and National Oncology Centre at Royal Hospital, shared a post on LinkedIn:
”I had the privilege of presenting our institutional, real-world experience with emicizumab in severe hemophilia A at the ISTH Middle East Summit standalone meeting in Paris, France.
Engaging in high-level discussions with colleagues from across the region was both inspiring and deeply enriching.
Even if the historic Paris heatwave meant our discussions weren’t the only things heating up!
It was a wonderful opportunity to connect, exchange insights, and collaborate.”
Stay updated with Hemostasis Today.
-
Sep 2, 2026, 18:26Strengthening Comprehensive Care for Inherited Bleeding Disorders in Ecuador – World Federation of Hemophilia
-
Sep 2, 2026, 18:24Zeeshan Ahmed Khattak: Managing Febrile Neutropenia in Hematology/Oncology and Transplant Patients
-
Sep 2, 2026, 18:22Mark Heyland: The Role of Thromboinflammation in Fracture Non-Union
-
Sep 2, 2026, 18:18Katie Gonzalez: Understanding the Hidden Risk of Inherited Thrombophilias
-
Sep 2, 2026, 18:14Beruni Narmada W: Rare Basal Vein of Rosenthal Thrombosis Presenting With Thalamic Haemorrhage
-
Sep 2, 2026, 18:03Omnia Ahmed: Effect of Hematocrit (HCT) on Coagulation Testing
-
Sep 2, 2026, 17:44John Thymis: Five E-Posters Presented at ESC Congress 2026 in Munich
-
Sep 2, 2026, 17:42Edward Lee Carter: In Antithrombotic Therapy, “More Protection” Can Become More Harm Surprisingly Quickly
-
Sep 2, 2026, 17:41Mohsin Raza: Why Is Anticoagulation Used During Hemodialysis?